MX387203B - Pirrolopirimidinas como potenciadores de cftr. - Google Patents

Pirrolopirimidinas como potenciadores de cftr.

Info

Publication number
MX387203B
MX387203B MX2019005822A MX2019005822A MX387203B MX 387203 B MX387203 B MX 387203B MX 2019005822 A MX2019005822 A MX 2019005822A MX 2019005822 A MX2019005822 A MX 2019005822A MX 387203 B MX387203 B MX 387203B
Authority
MX
Mexico
Prior art keywords
sup
compounds
cftr
cystic fibrosis
pyrrolopyrimidines
Prior art date
Application number
MX2019005822A
Other languages
English (en)
Spanish (es)
Other versions
MX2019005822A (es
Inventor
Atli Thorarensen
Christoph Wolfgang Zapf
Daniel Elbaum
David Christopher Limburg
Ivan Viktorovich Efremov
John Paul Mathias
Joseph Walter Strohbach
Lori Krim Gavrin
Rajiah Aldrin Denny
Original Assignee
Cystic Fibrosis Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cystic Fibrosis Found filed Critical Cystic Fibrosis Found
Publication of MX2019005822A publication Critical patent/MX2019005822A/es
Publication of MX387203B publication Critical patent/MX387203B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
MX2019005822A 2016-11-18 2017-11-17 Pirrolopirimidinas como potenciadores de cftr. MX387203B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423919P 2016-11-18 2016-11-18
PCT/US2017/062148 WO2018094137A1 (en) 2016-11-18 2017-11-17 Pyrrolopyrimidines as cftr potentiators

Publications (2)

Publication Number Publication Date
MX2019005822A MX2019005822A (es) 2019-09-09
MX387203B true MX387203B (es) 2025-03-18

Family

ID=62144793

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005822A MX387203B (es) 2016-11-18 2017-11-17 Pirrolopirimidinas como potenciadores de cftr.
MX2021012639A MX2021012639A (es) 2016-11-18 2017-11-17 Pirrolopirimidinas como potenciadores de cftr.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012639A MX2021012639A (es) 2016-11-18 2017-11-17 Pirrolopirimidinas como potenciadores de cftr.

Country Status (22)

Country Link
US (5) US10301315B2 (enExample)
EP (2) EP4424311A3 (enExample)
JP (3) JP6978507B2 (enExample)
KR (2) KR102585398B1 (enExample)
CN (2) CN110337294B (enExample)
AU (2) AU2017362350B2 (enExample)
CA (1) CA3044050A1 (enExample)
CL (1) CL2019001334A1 (enExample)
CO (1) CO2019005993A2 (enExample)
CR (1) CR20190292A (enExample)
DO (1) DOP2019000126A (enExample)
EC (1) ECSP19043120A (enExample)
ES (1) ES2983686T3 (enExample)
IL (3) IL314404B1 (enExample)
MX (2) MX387203B (enExample)
PE (1) PE20200739A1 (enExample)
PH (1) PH12019501098A1 (enExample)
PL (1) PL3541390T3 (enExample)
RU (2) RU2757457C2 (enExample)
SG (1) SG10202106949XA (enExample)
UA (1) UA125400C2 (enExample)
WO (1) WO2018094137A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2800565T3 (pl) 2012-01-06 2020-09-21 Lundbeck La Jolla Research Center, Inc. Związki karbaminianowe i sposoby ich wytwarzania oraz zastosowanie
PT3203840T (pt) 2014-10-06 2020-10-27 Vertex Pharma Moduladores do regulador da condutância transmembranar da fibrose quística
MA44126A (fr) * 2015-12-22 2018-10-31 Proteostasis Therapeutics Inc Méthodes de traitement de maladies et troubles pulmonaires
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
UA125400C2 (uk) * 2016-11-18 2022-03-02 Цистік Фіброзис Фаундейшн Піролопіримідин як потенціатор трансмембранної провідності при муковісцидозі (cftr)
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
RU2753056C2 (ru) * 2016-12-16 2021-08-11 Систик Файбросис Фаундейшн Бициклические гетероарильные производные в качестве стимуляторов cftr
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Ｃｆｔｒ調節劑之結晶形式及組合物
MA51039A (fr) 2017-12-08 2020-10-14 Vertex Pharma Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
SI3752510T1 (sl) 2018-02-15 2023-03-31 Vertex Pharmaceuticals Incorporated Makrocikli kot modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki iz le-teh, njihova uporaba pri zdravljenju cistične fibroze in postopek za njihovo proizvodnjo
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AR118555A1 (es) 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
JP2022537667A (ja) * 2019-06-10 2022-08-29 ノバルティス アーゲー Ｃｆ、ｃｏｐｄ、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体
AU2020313422A1 (en) 2019-07-15 2022-01-27 Novartis Ag Formulations of (S)-3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
SI4013741T1 (sl) 2019-08-14 2024-06-28 Vertex Pharmaceuticals Incorporated Postopek za izdelavo cftr-modulatorjev
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN111138439B (zh) * 2020-01-17 2021-06-25 厦门大学 氟代吡咯并嘧啶类化合物及其制备方法和应用
US20230192700A1 (en) 2020-03-06 2023-06-22 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
US20230277550A1 (en) 2020-08-20 2023-09-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for Treating Respiratory Diseases Characterized by Mucus Hypersecretion
EP4259139A1 (en) 2020-12-10 2023-10-18 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TW202425990A (zh) * 2022-11-02 2024-07-01 南韓商日東製藥股份有限公司 包含ｃｆｔｒ調節劑化合物之點眼用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0674641B1 (en) * 1992-12-17 1999-03-03 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
IL149462A0 (en) * 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
AU2002310187A1 (en) * 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
US20050008640A1 (en) * 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
TW201307354A (zh) * 2005-12-29 2013-02-16 Abbott Lab 蛋白質激酶抑制劑
EA200801968A1 (ru) * 2006-03-11 2009-02-27 Вернэлис (Р&Д) Лтд. Пирролопиримидиновые производные, используемые в качестве ингибиторов hsp90
KR20130087054A (ko) * 2006-04-04 2013-08-05 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
JP2011503103A (ja) * 2007-11-07 2011-01-27 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド タンパク質輸送の調節方法
ME02230B (me) * 2009-01-08 2016-02-20 Curis Inc Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
US20130123281A1 (en) 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
US8828998B2 (en) * 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014060431A1 (en) * 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2015091532A1 (en) * 2013-12-19 2015-06-25 Almirall, S.A. Pyrrolopyrimidine derivatives as pi3k inhibitors
UA125400C2 (uk) * 2016-11-18 2022-03-02 Цистік Фіброзис Фаундейшн Піролопіримідин як потенціатор трансмембранної провідності при муковісцидозі (cftr)

Also Published As

Publication number Publication date
RU2019118623A3 (enExample) 2021-03-18
ECSP19043120A (es) 2019-08-30
CN115850268B (zh) 2025-06-27
IL314404A (en) 2024-09-01
IL314404B1 (en) 2025-09-01
JP2020510668A (ja) 2020-04-09
AU2017362350A1 (en) 2019-06-20
EP4424311A2 (en) 2024-09-04
UA125400C2 (uk) 2022-03-02
IL296279A (en) 2022-11-01
US20210171534A1 (en) 2021-06-10
KR102824092B1 (ko) 2025-06-25
CN115850268A (zh) 2023-03-28
BR112019010167A2 (pt) 2019-09-17
CN110337294A (zh) 2019-10-15
AU2022201816A1 (en) 2022-04-07
JP7360434B2 (ja) 2023-10-12
AU2022201816A8 (en) 2022-04-21
US20180141954A1 (en) 2018-05-24
IL266668B (en) 2022-10-01
EP3541390B1 (en) 2024-05-01
PL3541390T3 (pl) 2024-09-09
AU2017362350B2 (en) 2021-12-23
KR20230146104A (ko) 2023-10-18
RU2757457C2 (ru) 2021-10-18
MX2021012639A (es) 2022-10-03
US20190225621A1 (en) 2019-07-25
US20200017512A1 (en) 2020-01-16
IL266668A (en) 2019-07-31
DOP2019000126A (es) 2019-08-30
JP7592814B2 (ja) 2024-12-02
CL2019001334A1 (es) 2019-11-15
EP3541390C0 (en) 2024-05-01
WO2018094137A1 (en) 2018-05-24
KR102585398B1 (ko) 2023-10-10
EP4424311A3 (en) 2024-12-18
ES2983686T3 (es) 2024-10-24
PH12019501098A1 (en) 2019-09-09
CR20190292A (es) 2019-09-03
RU2019118623A (ru) 2020-12-21
RU2021129721A (ru) 2021-11-26
JP2022024023A (ja) 2022-02-08
MX2019005822A (es) 2019-09-09
JP6978507B2 (ja) 2021-12-08
US20230250100A1 (en) 2023-08-10
EP3541390A4 (en) 2020-06-24
PE20200739A1 (es) 2020-07-24
US10301315B2 (en) 2019-05-28
EP3541390A1 (en) 2019-09-25
JP2023182694A (ja) 2023-12-26
CA3044050A1 (en) 2018-05-24
CO2019005993A2 (es) 2019-07-31
AU2022201816B2 (en) 2024-02-15
US10494374B2 (en) 2019-12-03
CN110337294B (zh) 2022-11-01
IL266668B2 (en) 2023-02-01
KR20190110088A (ko) 2019-09-27
NZ754085A (en) 2025-05-02
SG10202106949XA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MX387203B (es) Pirrolopirimidinas como potenciadores de cftr.
MX391651B (es) Derivados de heteroarilo biciclico como potenciadores de cftr.
BR112018007161A2 (pt) pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso
PH12018500088A1 (en) Substituted tricyclics and method of use
BR112018007145A2 (pt) ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso
CU20120139A7 (es) Derivado de piridina y pirazina para el tratamiento de fibrosis quística(cf)
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
BR112018072047A2 (pt) moduladores da proteína reguladora de condutância transmembranar de fibrose cística
CL2008003494A1 (es) Compuestos derivados de 4-(2-amino-1-hidroxietil)fenol; composicion farmaceutica; combinacion; y uso de los compuestos como agonistas del receptor adrenergico beta2 para el tratamiento de una enfermedad pulmonar, asma, enfermedad pulmonar obstructiva cronica, glaucoma, trastornos neurologicos, trastornos cardiacos, inflamacion.
JP2010504973A5 (enExample)
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
JP2016540749A5 (enExample)
CO6640319A2 (es) Formulación en polvo seca que comprende una droga antimuscarínica
JP2018505192A5 (enExample)
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
MY196804A (en) Class of bifunctional compounds with quaternary ammonium salt structure
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
EA029678B9 (ru) Четвертичные соли пиперидиния
JP2014517034A5 (enExample)
EA201070056A1 (ru) N-оксид силденафила в качестве пролекарства
BR112017008790A2 (pt) cromanos substituídos e métodos de uso
CY1114902T1 (el) Ανταγωνιστες cgrp υποδοχεα